Novartis became the sixth drugmaker to bring a legal challenge to the U.S. Supreme Court over the Inflation Reduction Act’s drug pricing provisions, escalating a multi‑year industry battle over government‑mandated price controls. The petitions target IR A mechanisms affecting manufacturer pricing and Medicare negotiations; the cases consolidate legal risk for the sector and could reshape the law’s implementation if the Court rules for plaintiffs.